Rising home prices and conservative borrowing have today's homeowners sitting on a record amount of potential cash. Today's mortgage holders saw their home equity increase by...Real Estateread more
Stocks have been grinding sideways, but technical analysts say once they breakout, the move to the upside could be powerful.Market Insiderread more
Shareholders are accusing Tesla of improperly valuing the SolarCity deal, providing flawed analysis and misleading investors, among other things. Their allegations were...Technologyread more
Stocks were barely changed. American Express gained, but Netflix was a notable laggard.Marketsread more
The probe by the U.S. attorney's office of the Northern District of California is in its early stages, the Journal reported, citing people familiar with the matter.Health and Scienceread more
The fresh round of cuts is on top of an estimated 4,500 temporary layoffs GM and its suppliers handed out to employees as of Friday.Autosread more
Here are the most important things to know about Tuesday before you hit the door including earnings from Nike and likely updates on Trump's trade deals.Marketsread more
The Mac Pro is the only major Apple computer to be assembled in the United States. Most of Apple's products, including the iPhone, are assembled in China and are facing tariff...Technologyread more
Think about the last TV show you recommended to a friend, or the last one that was recommended to you. Odds are, it was from a premium service like HBO, Netflix or Amazon.Entertainmentread more
SpaceX is deep into development of its Starship rocket, with recent updates from CEO Elon Musk showing the first one under construction.Investing in Spaceread more
The new wireless earbuds, codenamed "Puget," are expected to come with an accelerometer and be able to monitor things like the distance run, calories burned, and pace of...Technologyread more
Dassault said it was offering $92.25 per share for Medidata, a slight discount to Medidata Solutions' closing price of $94.75 on June 11.
"It's a logical evolution of the scope of what we do," Bernard Charles, chairman and CEO of Dassault Systemes, told CNBC's "Street Signs Europe" on Wednesday.
"Life science is going to go through an accelerated digitization of its own processes, basically. That's the motivation for Dassault Systemes to buy Medidata Solutions," Charles said.
Medidata's software is used to help clinics manage their back-office operations and their data, and it provides analytics tools so they can make sense of massive amounts of information. Medical device companies also use it to track the process of their clinical trials.
"Medidata has always been an extremely well-run company and a juggernaut in their space," said Bijan Salehizadeh, a medical technology investor at NaviMed Capital. "It's an A-plus asset."
The deal comes as the M&A market picks up for fast-growth software companies. Google acquired data analytics company Looker last week for $2.6 billion, and Salesforce followed on Monday with its biggest deal ever — the $15.3 billion purchase of Tableau Software.
Medidata, which competes with health software from vendors such as IBM, Oracle and Veeva, was founded in 1999 and went public 10 years later. Revenue increased 17% last year to $635.7 million and the company reported net income of $51.9 million. It currently has a market value of $5.9 billion, and the stock has climbed 17% in the past year. It gained an additional 6% after hours on the deal news.
Dassault sells software to transportation, aerospace and life sciences companies to help them digitize their businesses. Its 3D design tools help businesses with virtual product designs and enable digital simulation in product development. With Medidata, Dassault can add growth without sacrificing profitability while also expanding in the lucrative medical market.
Shares of Dassault Systemes slipped over 1% during mid-morning trade.
"It's about the diversification of their business," said Matthew Holt, managing director at private equity firm New Mountain Capital. "They understand regulated markets already, so life sciences wouldn't spook them."
— Ari Levy contributed to this report.